Table 1.
Demographic Characteristics of Participants at First Evaluable Visit According to Tenofovir Diphosphate in Dried Blood Spots Categories
| TFV-DP (fmol/punch) | ||||
|---|---|---|---|---|
| Characteristic | All Participants (n = 451) | BLQ to <800 (n = 58) | 800 to <1650 (n = 165) | ≥1650 (n = 228) |
| Age, median (IQR) | 46 (37–53) | 42 (34–51) | 45 (39–51) | 49 (38–55) |
| Sex, n (%) | ||||
| Male | 380 (84) | 49 (84) | 141 (85) | 190 (83) |
| Female | 71 (16) | 9 (16) | 24 (15) | 38 (17) |
| Race/ethnicity, n (%) | ||||
| Black | 85 (19) | 18 (31) | 37 (22) | 30 (13) |
| White | 257 (57) | 23 (40) | 96 (58) | 138 (61) |
| Hispanic | 89 (20) | 14 (24) | 30 (18) | 45 (20) |
| Other | 20 (4) | 3 (5) | 2 (1) | 15 (7) |
| Body mass index, kg/m2, n (%) | ||||
| <18.5 | 18 (4) | 2 (3) | 3 (2) | 13 (6) |
| 18.5–25 | 191 (42) | 23 (40) | 60 (36) | 108 (47) |
| 25–30 | 149 (33) | 19 (33) | 58 (35) | 72 (32) |
| >30 | 93 (21) | 14 (24) | 44 (27) | 35 (15) |
| eGFR, mL/min/1.73 m2, median (IQR) | 87 (73–101) | 96 (80–112) | 89 (76–104) | 84 (70–97) |
| CD4+ T-cell count, cells/mm3, n (%) | ||||
| <200 | 48 (11) | 12 (21) | 18 (11) | 18 (8) |
| 200–350 | 66 (15) | 10 (17) | 24 (15) | 32 (14) |
| 350–500 | 66 (15) | 8 (14) | 22 (13) | 36 (16) |
| >500 | 271 (60) | 28 (48) | 101 (61) | 142 (62) |
| VL, copies/mL,a median (IQR) | 119 (37–710) | 1055 (140–34 575) | 71 (31–397) | 63 (32–187) |
| Type of ART, n (%) | ||||
| NNRTI-based | 119 (26) | 10 (17) | 63 (38) | 46 (20) |
| INSTI-based | 159 (35) | 22 (38) | 52 (32) | 85 (37) |
| b/PI-based | 111 (25) | 17 (29) | 28 (17) | 66 (29) |
| Multiclass | 62 (14) | 9 (16) | 22 (13) | 31 (14) |
| Time on current anchor drug, n (%) | ||||
| <6 months | 74 (16) | 6 (10) | 32 (19) | 36 (16) |
| ≥6 months | 377 (84) | 52 (90) | 133 (81) | 192 (84) |
| Pharmacologic booster, n (%) | ||||
| No | 223 (49) | 23 (40) | 101 (61) | 99 (43) |
| Yes | 228 (51) | 35 (60) | 64 (39) | 129 (57) |
| Self-reported adherence, %, median (IQR) | ||||
| 3-day | 100 (100–100) | 100 (72–100) | 100 (100–100) | 100 (100–100) |
| 30-day | 100 (93–100) | 90 (60–100) | 100 (92–100) | 100 (99–100) |
| 3-month | 98 (90–100) | 84 (62–90) | 98 (90–100) | 100 (95–100) |
Abbreviations: ART, antiretroviral therapy; BLQ, below limit of quantification; b/PI, boosted protease inhibitor; eGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus; INSTI, integrase strand-transfer inhibitor; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; TFV-DP, tenofovir diphosphate; VL, viral load.
aLV for viremic participants (≥20 copies/mL).